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The allocation of organs and the optimal form of postoperative man-
agement are two of the most important issues in renal transplantation. On 
1 January 1986, a system for equitable deployment of cadaveric organs was 
put into place at the University of Pittsburgh Transplantation Center [1]. 
The system provided merit points for time waiting, quality of antigen 
match, degree of presensitization as reflected by a preformed antibody 
analysis (PRA), medical urgency, and logistical factors which would add to 
the risk by increasing preservation time. The point system was a step 
toward avoiding ad hoc decisions about who would receive a given kidney 
and a movement toward computerization in selection. 
Ultimately, the foregoing point system was adopted essentially with-
out change for national use by the United Network for Organ Sharing 
(UNOS), a private and previously voluntary organization which had been 
given by law the responsibility for developing a distribution scheme. How-
ever, the influence of such a system which systemically assures equitable 
access for all patients, including those at high medical and immunologic 
risk, has never been assessed. 
It is our intention to analyze here our experience with the point sys-
tem, with particular reference to the effect of immunosuppressive regi-
mens. 
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Methods 
Four hundred and sixty-three renal transplantations were performed at the Univer-
sity of Pittsburgh hospitals (Presbyterian-University Hospital and Children's Hospital of 
Pittsburgh) between 1 January 1986 and 31 December 1987. Two of the kidneys were 
from living-related donors and were excluded from analysis. Similarly excluded were 11 
cases of cadaver kidney transplantation in conjunction with a liver or heart transplant. 
Otherwise, there were no exclusions whatsoever in the 450 consecutive cadaveric kidney 
transplantations. 
Case Material 
Three hundred and eighty-seven adults, whose mean age was 39.6 ± 15.4 (SD) 
years, received 407 transplants. The most common disease of the native kidneys was 
glomerulonephritis. Eighty-five of the adult recipients (22%) were diabetics, almost all 
type 1. Thirty-eight children received 43 transplants; 25 were 10-18 years old and 13 were 
6 months to 9 years old. 
Tissue Typing 
The HLA typing for all donors and all recipients was carried out in an accredited 
laboratory in which all known class 1 and class 2 antigens can be measured. 
Antidonor antibodies were systematically looked for, and crossmatches with current 
recipient sera were performed in every case. A negative crossmatch was required in most 
cases, but in 39 instances, mostly involving highly sensitized recipients who had been 
waiting for long periods of time, transplantation was performed in spite of a weakly 
positive or doubtfully positive cytotoxic crossmatch. This experience has been reported 
separately [2] and will not be further discussed in this paper, except to mention that the 
results were not materially degraded from those in the overall group of highly sensitized 
recipients who had unequivocally negative crossmatches. 
Point Allocation System 
The Pittsburgh allocation system ranks potential recipients of a given kidney on the 
basis of several factors [1]. Waiting time, defined as beginning with the date of referral, 
can account for up to 10 points. Each class I or class 2 antigen match between donor and 
recipient accounts for two points, for a potential total of 12 if there is complete HLA 
identity. Every 10% of preformed antibody analysis (PRA; also called panel reactive 
antibody) accounts for one point, for a potential total of 10 points if there are antibodies 
against all of the lymphocyte test panel (100% PRA). Finally, medical urgency or logistic 
factors can add points, although these are rarely used. Thus, the system gives priority to 
those who have waited the longest, those with the best antigen match, and those with the 
greatest degree of presensitization who have a negative crossmatch. 
Operative Procedures 
Renal transplantation was with the standard operation [3], but using many varia-
tions when indicated. Because of the large number of older recipients, hypogastric to renal 
arterial anastomoses were not commonly performed, and in the vast majority, a Carrell 
patch of aorta containing the renal arterial orifice(s) was anastomosed to the external iliac 
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artery. Ureteral reconstruction was with a nipple-tunnel technique [3] or with modifica-
tions of the extra-vesical operation of Lich et al. [4]. 
In the 1986-1987 period, the organs from all local donors, and from the majority of 
donors in distant centers, were removed with the technique developed for multiple organ 
harvest [5, 6]. In our center, the presence of a long cold ischemia time has not had an 
adverse affect on ultimate outcome [7], although the need for early postoperative dialysis 
increases with time. 
Immunosuppression 
During 1986, all patients were managed initially with ciclosporin and prednisone. In 
1987, just under half of the recipients were started on ciclosporin, azathioprine and pred-
nisone. Variations of this triple-drug regimen were described in 1984 at the International 
Transplantation Society [8-10] or shortly after [11]. Earlier, the combination of ciclospo-
rin and azathioprine had been tested in primates by Reitz et al. [12] and synergism was 
demonstrated in rats and dogs by Squiffiet et al. [13]. By the time of the 1986 meeting in 
Helsinki of the International Transplantation Society, more than a dozen papers describ-
ing the advantages of three-drug or four-drug therapy were presented. 
OKT3 was used for steroid-resistant rejection episodes [14]. 
Statistical Methods 
Actuarial patient and graft survivals were calculated for the 2-year period. Statistical 
analysis was performed using BMPD Software; significance was assessed by the Mantel-
Cox test. 
Results 
Patient Survival and Causes of Death 
Four hundred and twenty-five patients received 450 kidneys. Overall 
actuarial patient survival at 1 and 2 years was 92 and 89% (fig. 1). Thirty-
seven (8.7%) of the 425 recipients have died. 
An effort was made to assign a single cause offailure (table I), realizing 
that before the time of death, multiple diagnoses almost invariably were 
applicable. However, an initial complication usually triggered a series of 
adverse consequences, often including infection as well as deterioration of 
the renal graft if this had not already occurred. The combinations of deadly 
complications after renal transplantation and how these interrelate have 
been described in detail previously, long before the advent of ciclosporin 
[ 15]. 
In over 80 % of the cases, there had been difficulty in maintaining 
good renal graft function (table I), either early because of acute rejection, 
or later because of chronic rejection or other factors. Apart from this fac-
tor, the most common principal cause of the events leading to death was 
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Fig. 1. Patient and graft survival for 1986-1987. 
Table l. Causes of death after renal transplantation 
Cause of death Graft 
functioning 
Infection 1 
Cardiovascular 4 
Gastrointestinal 1 
Respiratory 0 
~alignancy 0 
Technical 0 
~iscellaneous 
(DIC, multiple organ, failure, 
hyperkalemia, bleed after biopsy) 
Unknown 0 
7 (19%) 
Graft removed or 
nonfunctioning 
12 
5 
4 
2 
3 
2 
30 (81 %) 
33 
Total 
13 
9 
5 
2 
4 
2 
37 
infection, usually caused by opportunistic organisms or viruses. For exam-
ple, 2 young men were given kidneys from a 23-year-old donor killed in a 
motorcycle accident. Later, the donor was proved to be a herpes simplex 
carrier. The two renal recipients died of herpes hepatitis 17 and 19 days 
postoperatively. The liver from this donor was given to a recipient who was 
being treated with acyclovir because of a 'fever blister' at the time of his 
operation; he escaped harm. 
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Table II. Matching in 418 cases, in which there was adequate donor and recipient typing: 
kidney function has been from 4 to 28 months 
Number of antigens matched 
6 
5 
4 
3 
2 
1 
o 
Functioning/total 
n 
1/2 
2/3 
8/13 
33/55 
82/113 
103/142 
53/90 
282/418 
% 
50 
67 
62 
60 
72 
73 
61 
67 
The second principal cause of death (9 patients) was cardiovascular 
disease. Gastrointestinal disease was also an important cause of death, 
with 2 lethal colonic perforations, 2 cases of severe upper gastrointestinal 
hemorrhage requiring emergency operations, and 1 case of liver failure 
(table I). A lymphoma caused the death of 1 patient. If diagnosed in time, 
these lymphomas usually involute with discontinuance or lightening of 
immunosuppression [16]. No deaths were caused by epithelial malignan-
cies in the 1986-1987 recipients. 
Miscellaneous causes of death included hemorrhage after a renal biop-
sy, a technical error in performing ureteroureteroneocystotomy, respira-
tory arrest during changing of a tracheostomy, and a respiratory arrest 
which may have been caused by an OKT3 infusion 12 h earlier. 
Graft Survival 
Overall Graft Survival. One- and 2-year actuarial graft survival was 72 
and 64% (fig. 1). Although a sophisticated examination of tissue typing 
was not part of this study, there was no obvious affect of tissue matching 
(table II). The incidence of current success was about the same with all 
levels of compatibility. 
Because some of the patients received more than one graft during the 
1986-1987 study period, the actual number of patients represented by the 
450 cadaveric transplantations was 425. Of these 425 patients, 388 (91 %) 
2 
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Fig. 2. Pediatric and adult graft survival for 1986-1987. 
Fig. 3. Primary and retransplant graft survival for 1986-1987. 
Table III. Fate of 425 recipients of 450 grafts 
Alive 
Off dialysis 
On dialysis 
Dead 
n 
388 
311 
77 
37 
% 
91.3 
73.2 
18.1 
8.7 
18 
.......... - .... - -
24 
35 
30 
are alive, and 311 (73 %) are off dialysis (table III). Thus, the gap between 
patient survival and graft survival shown in figure 1 underestimates the 
effectiveness of renal transplantation, in terms of liJ:)erating patients from 
dialysis (table III). 
Adults versus Children. Adults and children did not differ significantly 
in overall graft survival (fig. 2). Of the 38 pediatric recipients of 43 grafts 4 
(10.5%) died, for a mortality that was similar to that in adults. 
Primary Transplantation versus Retransplantation. The results in 
transplanting patients for the first time were slightly but not significantly 
better than the results of retransplantation (fig. 3). 
3 
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Fig. 4. Graft survival for PRA less than and greater than 40%. 
Fig. 5. Graft survival for two- and three-drug immunosuppression. 
Transplantation to 'Clean' versus Sensitized Patients. Grafts in pa-
tients with a PRA less than 40% had a significantly (p < 0.025) better 
survival than in patients with a PRA greater than 40% (fig. 4). In most 
reports, a great preponderance of highly sensitized patients have had pre-
vious transplantations and because of this, retransplantations have been 
less successful. The discordance with this expectation was due to the fact 
that many highly sensitized patients were undergoing primary transplanta-
tion in this series. 
Effect of Triple- versus Double-Drug Immunosuppression 
Overall Results. In the subgroup of patients treated beginning in Jan-
uary 1987 with ciciosporin, azathioprine, and prednisone, graft survival 
has been significantly better (p < 0.02) than with the cohort of patients 
receiving ciciosporin and steroids alone (fig. 5). The actuarial projections 
at 1 year predict 86% survival with triple therapy versus 69% with double 
therapy. 
Adults versus Children. The advantage with triple-drug therapy was 
approximately the same whether the recipients were in the adult or pediat-
ric population (fig. 6), although the numbers in the pediatric group were 
too small to permit statistical significance. 
6 
8 
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Fig. 6. Pediatric and adult graft sur-
vival with two- and three-drug immuno-
suppression. 
Fig. 7. Primary and retransplant graft 
survival with two- and three-drug immu-
nosuppression. 
Fig. 8. Graft survival for PRA less 
than and greater than 40 % with two- and 
three-drug immunosuppression. 
Primary Transplantation versus Retransplantation. The advantage of 
triple-drug therapy was evident in recipients of primary grafts as well as in 
those undergoing retransplantation, and in the larger group of primary 
transplantations, the advantage was statistically significant (p < 0.025) 
(fig. 7). 
Low versus High PRA. Triple-drug therapy was advantageous for 
highly sensitized patients who have a predicted I-year survival of 76%, 
even though they did not do as well as patients with low PRAs who have a 
projected I-year survival of 88 % (fig. 8). In contrast, patients in our 2-year 
sample of double-drug therapy including contemporaneous 1987 controls, 
have a I-year actuarial survival of 57 % when highly sensitized versus 71 % 
with a low PRA (fig. 8). Thus, triple-drug therapy has upgraded survival in 
both the favorable and immunologically unfavorable patient categories. 
7 
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Discussion 
Equal access to organs for patients in need is a matter of intense con-
cern to the public as well as to health care providers. The point system [1] 
was designed to simplify recipient selection and to remove from the pro-
cess the kind of bias against certain classes of potential recipients that 
could easily creep into an ad hoc system of patient selection. For example, 
there are no advantages or disadvantages for being old, afflicted by dis-
eases of other organ systems, belonging to specific ethnic groups or reli-
gious persuasions, or being foreign-born. 
One of the major arguments against the point system [17] comes from 
a school-of-thought that seeks to maximize graft survival by transplanting 
to the 'best' recipients, namely those who are young, healthy, and with low 
PRAs. The point system assures that highly sensitized patients will come to 
transplantation and considers irrelevant the question of obtaining good 
graft survival curves. In our series, 1 of every 7 patients had a PRA greater 
than 40%, connoting a poorer prognosis in all multicenter collections. The 
average age of adults in this sample was 39.6 ± 15.4 years. 
The possibility that the point system could degrade results could be 
argued from our own experience during this bellwether period of 1986-
1987. Even in our first trials with ciclosporin-steroid therapy in 1979-
1980, the I-year graft survival was with primary cadaveric transplantation 
80 % [18], and, in 1981, this expectation at I-year rose to nearly 90 % [19]. 
In these patients with whom ciclosporin-steroid therapy was first tried and 
standardized, the results in 1979-1981 were superior to those in 1986-
1987, even though all of the earlier work was done without any means of 
pharmacologic monitoring with ciclosporin blood or plasma assays. Al-
though the recipients were not highly selected, they were younger than in 
the 1986-1987 period, had a lower incidence of diabetes mellitus, and had 
less disease of other organ systems. 
Nevertheless, acceptable results were obtained in the first 2 years of 
the point system. Of equal importance, the triple-drug trials of 1987 dem-
onstrated the possibility of achieving even better levels of success. The 
additive and possibly synergistic combination of ciclosporin, azathio-
prine, and steroids has been recognized worldwide since its introduction 
in 1984 [8-10] and 1985 [11]. The superiority of and probable safety of 
the triple-drug regimen has been established in several recent randomized 
trials and our observations with shorter follow-up are in accord with these 
claims. 
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In the United States, and for the first time, the establishment of the 
United Network of Organ Sharing Kidney Transplant Registry will allow 
assessment of results after all of the cadaveric renal transplantations 
nationwide. From these data, analyses should begin to show if any of the 
factors used to compute points for the recipient scores will affect, either 
favorably or adversely, graft or patient life survival curves. Since our own 
experience with the point system precedes by almost 2 years that of all of 
the other centers which eventually were asked to adopt the system, some 
inkling of the implications of details of the point system will be watched for 
with interest in our patients. For example, a spectrum of donor-recipient 
matching is ensured by the point system, but so far, no major affect on the 
outcome has been identifiable as the result of extremely good or extremely 
poor compatibility or any permutations in between. The effect of age itself 
may prove to be important. In our own series, a high number of complica-
tions which would be expected in older patients were seen including 
colonic perforations, and many lethal cardiovascular complications. 
Probably, it will be a number of years before enough data can be col-
lected to justify concluding that easy entry into candidacy for high-risk 
patients and equitable access to organs thereafter will lead to truly ineffi-
cient use of organs. Even if this proves to be a valid conclusion, the loss of 
organs is not apt to be so great as to encourage an idolatry of survival 
numbers or worship at the altar of statistical morality. 
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